Overview

Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
0
Participant gender:
All
Summary
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Rabin Medical Center
Treatments:
Omalizumab
Criteria
Inclusion Criteria:

- diagnosis of chronic idiopathic urticaria for 3 months

- failure on treatment with at least 2 antihistamins and systemic corticosteroids or
cyclosporin

Exclusion Criteria:

- physical or cholinergic urticaria

- past treatment in Omalizumab i nprevious year

- parasitic infection

- malignancy in last 5 years

- known sensitivity to Omalizumab